Aspira Pathlab (540788)

Score breakdown: P/E: 0/3 · ROCE: 1/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Operates in healthcare services/pathology, a sector with long-term structural demand in India.
• Trailing ROCE of 17.37% and ROE of 13.19% indicate decent prior capital efficiency.
• Small market cap of ₹32 Cr leaves room for growth if operations stabilize.
• Latest quarterly sales of ₹5 Cr show some operating base, albeit unprofitable.

Concerns

• Latest quarter net loss of ₹2 Cr on revenue of ₹5 Cr implies a 40% net loss margin.
• Sales down 5.36% and profit down 510.53% reflect severe operational deterioration.
• Piotroski F-Score of 3/9 signals weak overall financial health.
• No dividend, P/B of 3.15, and price of ₹31 against a 52-week range of ₹49–₹119 offer no margin of safety.

AI Analysis

At first glance, Aspira Pathlab sits in an industry I respect—healthcare services—but that alone does not justify investment. At ₹31, the market cap is just ₹32 crore. The latest quarter tells an alarming story: revenue of ₹5 crore and a net loss of ₹2 crore, implying a 40% net loss margin. Sales have declined 5.36% and profit growth has collapsed by 510.53%. This is not the earning power I look for. The trailing ROE of 13.19% and ROCE of 17.37% look respectable, but they are backward-looking and likely being eroded by current losses. Book value is ₹9.84; the price-to-book of 3.15 means I am paying over three times net assets for a business that is destroying profits. A P/E of 39.91 is meaningless when earnings are falling and the company is loss-making. There is no dividend, so the only return must come from share price—an uncertain bet. Graham would demand a margin of safety. I see none. The Piotroski F-Score of 3/9 is a clear red flag, indicating weak fundamental health. The 52-week range of ₹49 to ₹119, with the current price at ₹31, suggests severe value erosion or a deeply distressed market; either way, existing shareholders have suffered. Promoter holding is not available, and without that transparency I cannot judge alignment. Maybe Aspira can turn around—healthcare diagnostics has structural demand—but a turnaround requires evidence: cost discipline, improving margins, and a clear path to positive cash flow. I do not see those signs yet. In Buffett's language, this is not a wonderful business at a fair price; it is a weak business at an uncertain price. I would put it in the too-hard pile and wait for demonstrable improvement before touching it.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer